



CrossMark

“RESPIRE: breathing new life into bronchiectasis.” Sanjay H. Chotirmall and James D. Chalmers. *Eur Respir J* 2018; 51: 1702444.

This article from the January 2018 issue of the *European Respiratory Journal* was originally published with an error in figure 1; the data relating to the 14- and 28-day treatment regimens for the RESPIRE 2 study had been transposed. The correct figure is as presented below. The article has been corrected and republished online.




FIGURE 1 Fixed effects meta-analysis pooling of the four RESPIRE study arms for the European Medicines Agency primary outcome of frequency of exacerbations versus matching placebo. DPI: dry powder inhalation. Additional integrated analyses performed by the US Food and Drug Administration are available from www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiInfectiveDrugs/AdvisoryCommittee/UCM584646.pdf